Gail Boudreaux

President, Chief Executive Officer & Director, Elevance Health

Search every verified Gail Boudreaux interview, podcast appearance, and on-the-record quote — each transcript cross-checked by AI and human review to confirm speaker identity. Gail Boudreaux, president and CEO of Elevance Health, reported at the company's 2026 annual meeting that Elevance Health generated $197.6 billion in operating revenue in 2025, a 13% increase from the prior year, and returned $4.1 billion to shareholders through dividends and share repurchases. She said the company was advancing its "whole health" approach by integrating physical, behavioral, pharmacy, and social care and scaling the use of artificial intelligence across operations. Boudreaux also noted that a shareholder proposal requesting an independent study on the impact of prohibiting corporate contributions to partisan political groups did not pass. During previous earnings calls in 2025, Boudreaux discussed challenges in the Medicaid and ACA markets. In the second quarter, she revised the full-year 2025 adjusted EPS guidance to approximately $30, citing elevated medical cost trends and slower-than-expected Medicaid rate alignment. She also described legal action against what she described as misuse of the independent dispute resolution process under the No Surprises Act, alleging that out-of-network providers had submitted inflated payment requests. In the third quarter, Boudreaux stated that Elevance Health was planning for at least a 125 basis point year-over-year decline in Medicaid margins and noted that if Congress allowed enhanced premium tax credits to expire, it would significantly impact 2026 membership. She emphasized that the company was prioritizing long-term performance over near-term expense leverage.